Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin-α1 in HBV-related ACLF
NCT03082885Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of thymosin alpha 1 in acute-on-chronic liver failure (ACLF) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Liver transplantation-free survival rate at 90 days. Started Apr 2017; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03082885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082885.